In addition to the corporate angle, I'm fine with a trading halt for something like palbo. It was a first in class drug with clear benefits, and the NDA submission was an early signal for the breast cancer caregivers.
The n+1th pd-1/pd-l1 drug isn't in comparable imo.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.